Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy
PA Frischmeyer-Guerrerio, M Masilamani, W Gu… - Journal of Allergy and …, 2017 - Elsevier
Background In our recent clinical trial, the addition of omalizumab to oral immunotherapy
(OIT) for milk allergy improved safety, but no significant clinical benefit was detected.
Objective We sought to investigate mechanisms by which omalizumab modulates immunity
in the context of OIT and to identify baseline biomarkers that predict subgroups of patients
most likely to benefit from omalizumab. Methods Blood was obtained at baseline and
multiple time points during a placebo-controlled trial of OIT for milk allergy in which subjects …
(OIT) for milk allergy improved safety, but no significant clinical benefit was detected.
Objective We sought to investigate mechanisms by which omalizumab modulates immunity
in the context of OIT and to identify baseline biomarkers that predict subgroups of patients
most likely to benefit from omalizumab. Methods Blood was obtained at baseline and
multiple time points during a placebo-controlled trial of OIT for milk allergy in which subjects …